# A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects

> **NCT06294275** · PHASE1 · COMPLETED · sponsor: **Longbio Pharma** · enrollment: 68 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **BIOLOGICAL:** LP-001 Dose 1 (Single)
- **BIOLOGICAL:** LP-001 Dose 2 (Single)
- **BIOLOGICAL:** LP-001 Dose 3 (Single)
- **BIOLOGICAL:** LP-001 Dose 4 (Single)
- **BIOLOGICAL:** LP-001 Dose 5 (Single)
- **BIOLOGICAL:** LP-001 Dose 6 (Single)
- **BIOLOGICAL:** Placebo (Single)
- **BIOLOGICAL:** LP-001 Dose 7 (Multiple)
- **BIOLOGICAL:** LP-001 Dose 8 (Multiple)
- **BIOLOGICAL:** Placebo (Multiple)

## Key facts

- **NCT ID:** NCT06294275
- **Lead sponsor:** Longbio Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-03
- **Primary completion:** 2023-08-16
- **Final completion:** 2023-08-16
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06294275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06294275, "A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06294275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*